Having trouble viewing this email? View in your browser.
img Valnera invitation

Dear Doctor,

We recently organized a symposium titled ‘Developing New Vaccines To Protect Against Infectious Diseases At Home And Abroad’ at this year’s 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). At this event, we revealed the LATEST TRIAL RESULTS of our NOVEL COVID-19 AND CHIKUNGUNYA VACCINES. In case you missed this event, we are delighted to share with you the ON-DEMAND RECORDING OF THE SYMPOSIUM.

The symposium included presentations on:


1. The portfolio approach –
Lessons learned from the UK Vaccine Task Forces response to COVID-19:

Prof. Adam Finn (UK)

2. Travel and the pandemic –
Challenges faced by specialist travel clinics and how travel changed:

Prof. Tomas Jelinek (Germany)

3. Leveraging established technologies –
An inactivated vaccine candidate (VLA2001) with a novel adjuvant combination to protect against COVID-19:

Prof. Adam Finn (UK)

Results of the COVID-19 vaccine candidate first-in-human Phase 1/2 study evaluating 3 dose levels (low, medium, high) for safety, tolerability and immunogenicity and more…

4. Emerging Infectious Disease –
Chikungunya as a public health threat and introduction to a novel vaccine candidate (VLA1553):

Prof. Tomas Jelinek (Germany)

Chikungunya vaccine - immunogenicity and safety results from a dose-escalation study

Chikungunya vaccine - immunogenicity and safety results from the Phase 3 pivotal study



For any further questions or information, don’t hesitate to contact us at communications@valneva.com



You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.

This newsletter has been sent to: $$EMAIL$$